Literature DB >> 2802800

Anticentromere antibody in patients without CREST and scleroderma: association with active digital vasculitis, rheumatic and connective tissue disease.

J A Goldman1.   

Abstract

This paper looks at the problem confronting a doctor evaluating a patient with anticentromere antibody who does not have evidence of disease along the spectrum from CREST (calcinosis, Raynaud's phenomenon, oesophageal dysmotility, sclerodactyly, telangiectasia) to progressive systemic sclerosis. Of 33 people with anticentromere antibody, 21 had CREST and two had scleroderma. Of the other 10 with a positive anticentromere antibody, three had systemic lupus erythematosus (two with digital vasculitis), three very active seronegative polyarthritis, three Raynaud's phenomenon, and one a claudication syndrome involving the legs. A positive antinuclear antibody test does not always indicate the presence of a connective tissue disease, but the presence of anticentromere antibody without systemic sclerosis or CREST often indicates the presence of another sometimes serious underlying rheumatic or connective tissue disease.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2802800      PMCID: PMC1003872          DOI: 10.1136/ard.48.9.771

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  17 in total

1.  Allergy in systemic lupus erythematosus. IgE levels and reaginic phenomenon.

Authors:  J A Goldman; G A Klimek; R Ali
Journal:  Arthritis Rheum       Date:  1976 Jul-Aug

2.  Detection of anticentromere antibodies using cloned autoantigen CENP-B.

Authors:  N Rothfield; D Whitaker; B Bordwell; E Weiner; J L Senecal; W Earnshaw
Journal:  Arthritis Rheum       Date:  1987-12

3.  Antinuclear, anticytoplasmic, and anti-Sjogren's syndrome antigen A (SS-A/Ro) antibodies in female blood donors.

Authors:  M J Fritzler; J D Pauls; T D Kinsella; T J Bowen
Journal:  Clin Immunol Immunopathol       Date:  1985-07

4.  Anticentromere antibody is not specific for connective tissue disease with a promising prognosis.

Authors:  S R Mitchell; G A McCarty; P Katz
Journal:  Arthritis Rheum       Date:  1985-09

5.  Immunomorphological characterisation of antinuclear antibodies in chronic liver disease.

Authors:  F Cassani; F B Bianchi; M Lenzi; U Volta; E Pisi
Journal:  J Clin Pathol       Date:  1985-07       Impact factor: 3.411

6.  The anticentromere antibody: disease specificity and clinical significance.

Authors:  F C Powell; R K Winkelmann; F Venencie-Lemarchand; J L Spurbeck; A L Schroeter
Journal:  Mayo Clin Proc       Date:  1984-10       Impact factor: 7.616

7.  Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee.

Authors: 
Journal:  Arthritis Rheum       Date:  1980-05

8.  Diversity of antinuclear antibodies in progressive systemic sclerosis. Anti-centromere antibody and its relationship to CREST syndrome.

Authors:  E M Tan; G P Rodnan; I Garcia; Y Moroi; M J Fritzler; C Peebles
Journal:  Arthritis Rheum       Date:  1980-06

9.  Anticentromere antibody. Clinical Correlations and association with favorable prognosis in patients with scleroderma variants.

Authors:  G A McCarty; J R Rice; M L Bembe; F A Barada
Journal:  Arthritis Rheum       Date:  1983-01

10.  Comparison of five assays for immune complexes in the rheumatic diseases. An assessment of their validity for rheumatoid arthritis.

Authors:  J S McDougal; M Hubbard; F C McDuffie; P L Strobel; S J Smith; N Bass; J A Goldman; S Hartman; G Myerson; S Miller; R Morales; C H Wilson
Journal:  Arthritis Rheum       Date:  1982-10
View more
  2 in total

Review 1.  Raynaud's phenomenon: its relevance to scleroderma.

Authors:  J J Belch
Journal:  Ann Rheum Dis       Date:  1991-11       Impact factor: 19.103

2.  Anti-centromere antibodies (ACA) in systemic sclerosis patients and their relatives: a serological and HLA study.

Authors:  N J McHugh; J Whyte; C Artlett; D C Briggs; C O Stephens; N J Olsen; N G Gusseva; P J Maddison; C M Black; K Welsh
Journal:  Clin Exp Immunol       Date:  1994-05       Impact factor: 4.330

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.